GlassScriptPhysician profile
Denise I Cubero-Walker
NPI 1679586879
$1,659.25
in general payments reported to CMS, 2019-2025
31 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $80.94 · 2022: $147 · 2023: $245 · 2024: $518 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $242.83 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $132.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $128.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.09 | 2020-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $84.02 | 2019-2025 | |
| Abbvie INC. | $81.72 | 2023-2025 | Ubrelvy |
| Daiichi Sankyo INC. | $69.75 | 2022-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $69.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.49 | 2022-2024 | |
| Lilly USA, LLC | $56.70 | 2020-2024 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $56.46 | 2019-2020 | |
| Exact Sciences Corporation | $53.35 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $52.76 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $50.53 | 2023-2024 | |
| Edwards Lifesciences Corporation | $49.48 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.49 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $44.90 | 2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $32.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.78 | 2023-2024 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $30.94 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $29.69 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $25.44 | 2023 | Gemtesa |
| Aimmune Therapeutics, INC. | $17.90 | 2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $17.81 | 2022 | |
| Mannkind Corporation | $17.11 | 2020 | |
| Esperion Therapeutics, INC. | $16.35 | 2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $14.50 | 2023 | Quviviq |
| Mylan Specialty L.P. | $14.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.35 | 2019 | |
| Valeritas, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Cubero-Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.